Carrick Therapeutics has appointed Dr Burt Adelman and Dr Clive Dix to its board.
Commenting on the appointments, Dr Elaine Sullivan, CEO of Carrick Therapeutics, said: “I am delighted to welcome two such renowned and successful entrepreneurs and thought leaders to the board. Both Dr Adelman and Dr Dix have extensive experience of leading drug development from laboratory to clinic, and we are fortunate to be benefitting from their expertise as we drive forward and expand our portfolio.
“We have made good progress in our first year, and will be making significant therapeutics announcements in the coming weeks and months.”
Dr Burt Adelman said: “The blend of world-class cancer researchers, drug development experts and the life science sector’s leading investors makes Carrick Therapeutics a truly exciting company. I look forward to working alongside my new colleagues on the board as we support Elaine to deliver Carrick Therapeutics’ vision of building Europe’s leading oncology company.”
Dr Clive Dix added: “Carrick Therapeutics’ potential is clear and our purpose profound – targeting the most aggressive and resistant forms of cancer in order to make a real difference to the lives of patients. I am excited to be working alongside the distinguished team working to achieve this.”